Table 2.
Percentage of drugs with indicated level of evidence per age group
| Age group (total number of drugs in age group overall and on WHO essential medicines list) | Authorized (A0) | High‐level evidence (A1/A2) | Low‐level evidence (B/C/D) | Guideline | ||||
|---|---|---|---|---|---|---|---|---|
| DPF (%) | WHO (%) | DPF (%) | WHO (%) | DPF (%) | WHO (%) | DPF (%) | WHO (%) | |
| Preterm (n = 73; n = 50) | 34 | 44 | 22 | 18 | 38 | 30 | 8 | 8 |
| Term (n = 252; n = 123) | 48 | 54 | 6 | 6 | 34 | 30 | 12 | 10 |
| Infant (n = 558; n = 218) | 60 | 72 | 6 | 5 | 29 | 18 | 5 | 5 |
| Young child (n = 658; n = 233) | 71 | 83 | 5 | 5 | 21 | 10 | 3 | 1 |
| Child (n = 727; n = 246) | 75 | 87 | 4 | 2 | 19 | 10 | 3 | 1 |
| Adolescent (n = 757; n = 246) | 79 | 89 | 11 | 3 | 15 | 7 | 3 | 1 |
AO: Authorized use; A1: systematic review or meta‐analysis with at least two studies of level A2; A2: randomized controlled trial with at least 4 points on the Jadad‐scale; B: comparative research with a maximum of 3 on the Jadad‐scale; C: non‐comparative research; D: consensus or expert opinion; Guidelines (HIV, oncology, and metabolic diseases); DPF, Dutch Pediatric Formulary; WHO, World Health Organization.